CN110051702A - 一种防治手足口病、流感的益生菌配方 - Google Patents
一种防治手足口病、流感的益生菌配方 Download PDFInfo
- Publication number
- CN110051702A CN110051702A CN201910491110.5A CN201910491110A CN110051702A CN 110051702 A CN110051702 A CN 110051702A CN 201910491110 A CN201910491110 A CN 201910491110A CN 110051702 A CN110051702 A CN 110051702A
- Authority
- CN
- China
- Prior art keywords
- foot
- influenza
- mouth disease
- hand
- probiotic formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种益生菌配方,尤其涉及一种防治手足口病、流感的益生菌配方。本发明的益生菌配方,每0.05毫升的益生菌配方溶液中含有:动物双歧杆菌Bb‑12:1.5~2.0亿个;嗜酸乳杆菌:1.5~2.0亿个;鼠李糖乳杆菌:1.5~2.0亿个;罗伊乳杆菌:0~2.0亿个。本发明的益生菌组合能够共生共存,可以诱导机体产生非特异性抗体,提高机体抵抗力;并可诱导机体产生对手足口病和流感的主要病原体产生特异性抗体,对手足口病和流感有一定的防治作用。
Description
技术领域
本发明涉及一种益生菌配方,尤其涉及一种防治手足口病、流感的益生菌配方。
背景技术
益生菌指可改善宿主肠内微生态的平衡,并对宿主有正面效益的活性微生物。益生菌有帮助营养物质的消化吸收;产生重要的营养物质;抵抗细菌病毒的感染,提升免疫力,可清除有害菌对身体的伤害等功能。
由于现在市场上的益生菌只是非特异性地在一定程度上提高机体抵抗力,并不能针对手足口病和流感的主要病原体产生特异性抗体,因此对这些疾病的防治并没有太明显的影响。
本发明专门研究并选择可诱导机体产生对手足口病和流感的主要病原体产生特异性抗体的益生菌进行组合,并保证这些益生菌能够共存共生。
发明内容
(1)要解决的技术问题
本发明为了克服现在市场上的益生菌只是非特异性地在一定程度上提高机体抵抗力,并不能针对手足口病和流感的主要病原体产生特异性抗体的缺点,本发明要解决的技术问题是提供一种防治手足口病、流感的益生菌配方。
(2)技术方案
为了解决上述技术问题,本发明提供了这样一种防治手足口病、流感的益
生菌配方,每0.05毫升的益生菌配方溶液中含有:
动物双歧杆菌Bb-12: 1.5~2.0亿个;
嗜酸乳杆菌: 1.5~2.0亿个;
鼠李糖乳杆菌: 1.5~2.0亿个;
罗伊乳杆菌: 0~2.0亿个。
优选地,每0.05毫升的益生菌配方溶液中含有:
优选地,每0.05毫升的益生菌配方溶液中含有:
优选地,每0.05毫升的益生菌配方溶液中含有:
本发明的上述益生菌是从肠道内500-1000种的益生菌中选择,选择已经证明是有益于人类生命和健康的益生菌,并且选择对流感或手足口病防治有帮助的益生菌,同时选择的上述益生菌能够共生共存。
本发明的益生菌配方的适应症有:
≤3岁的肠道菌群***“成人化”前;
65岁后肠道菌群显著变化后;
慢性腹泻者;
长期服用抗生素者;
湿疹,过敏等。
在流感季节前1-2个月开始服用防治流感的益生菌组合,每天服用1滴,一滴即0.05毫升,连续服用2-3周。
在手足口病季节前1-2个月开始服用防治手足口病的益生菌组合,每天服用1滴,一滴即0.05毫升,连续服用3-5周。
(3)有益效果
本发明的益生菌组合能够共存共生,诱导机体提高非特异性抗体,提高机体抵抗力。
诱发机体产生对手足口病和流感的主要病原体产生特异性抗体,对手足口病和流感有一定的防治作用。
具体实施方式
实施例1
一种防治手足口病、流感的益生菌配方,每0.05毫升的益生菌配方溶液中含有:
用上述配方防治流感(甲流、乙流)。
实施例2
一种防治手足口病、流感的益生菌配方,每0.05毫升的益生菌配方溶液中含有:
用上述配方防治流感(甲流、乙流)和手足口病。
实施例3
一种防治手足口病、流感的益生菌配方,每0.05毫升的益生菌配方溶液中含有:
用上述配方防治流感(甲流、乙流)和手足口病。
实施例4
一种防治手足口病、流感的益生菌配方,每0.05毫升的益生菌配方溶液中含有:
用上述配方防治流感(甲流、乙流)和手足口病。
实施例5
一种防治手足口病、流感的益生菌配方,每0.05毫升的益生菌配方溶液中含有:
用上述配方防治流感(甲流、乙流)和手足口病。
本发明的上述益生菌是从肠道内500-1000种的益生菌中选择,选择已经证明是有益于人类生命和健康的益生菌,并且选择对流感或手足口病防治有帮助的益生菌,同时选择的上述益生菌能够共生共存。
本发明的益生菌配方的适应症有:
≤3岁的肠道菌群***“成人化”前;
65岁后肠道菌群显著变化后;
流感(甲流、乙流);
手足口病;
慢性腹泻者;
长期服用抗生素者;
湿疹,过敏等。
在流感季节前1-2个月开始服用防治流感的益生菌组合,每天服用1滴,一滴即0.05毫升,连续服用2-3周。
在手足口病季节前1-2个月开始服用防治手足口病的益生菌组合,每天服用1滴,一滴即0.05毫升,连续服用3-5周。
本发明的益生菌组合能够共存共生,帮助机体提高非特异性抗体,提高机体抵抗力。诱发机体产生对手足口病和流感的主要病原体产生特异性抗体,对手足口病和流感有一定的防治作用。
以上所述实施例仅表达了本发明的优选实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形、改进及替代,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (4)
1.一种防治手足口病、流感的益生菌配方,其特征在于,每0.05毫升的益生菌配方溶液中含有:
动物双歧杆菌Bb-12: 1.5~2.0亿个;
嗜酸乳杆菌: 1.5~2.0亿个;
鼠李糖乳杆菌: 1.5~2.0亿个;
罗伊乳杆菌: 0~2.0亿个。
2.根据权利要求1所述的一种防治手足口病、流感的益生菌配方,其特征在于,每0.05毫升的益生菌配方溶液中含有:
3.根据权利要求1所述的一种防治手足口病、流感的益生菌配方,其特征在于,每0.05毫升的益生菌配方溶液中含有:
4.根据权利要求1所述的一种防治手足口病、流感的益生菌配方,其特征在于,每0.05毫升的益生菌配方溶液中含有:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910491110.5A CN110051702A (zh) | 2019-06-06 | 2019-06-06 | 一种防治手足口病、流感的益生菌配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910491110.5A CN110051702A (zh) | 2019-06-06 | 2019-06-06 | 一种防治手足口病、流感的益生菌配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110051702A true CN110051702A (zh) | 2019-07-26 |
Family
ID=67325646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910491110.5A Pending CN110051702A (zh) | 2019-06-06 | 2019-06-06 | 一种防治手足口病、流感的益生菌配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110051702A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031313A (zh) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | 基于益生菌的组合物及其在预防和/或治疗呼吸性病变和/或感染以及改善肠功能中的用途 |
CN101336938A (zh) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | 益生菌在制备治疗与预防手足口病组合物中的应用 |
-
2019
- 2019-06-06 CN CN201910491110.5A patent/CN110051702A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031313A (zh) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | 基于益生菌的组合物及其在预防和/或治疗呼吸性病变和/或感染以及改善肠功能中的用途 |
CN101336938A (zh) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | 益生菌在制备治疗与预防手足口病组合物中的应用 |
Non-Patent Citations (3)
Title |
---|
GAREAU MG等: "Probiotics and the gut microbiota in intestinal health and disease", 《NAT REV GASTROENTEROL HEPATOL》 * |
尹斐弘等: "儿童重症手足口病肠道菌群和肠道黏膜通透性的研究进展", 《中国微生态学杂志》 * |
邹杨等: "益生菌防治呼吸道感染的研究进展", 《中国当代医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olaimat et al. | The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19 | |
Minelli et al. | Relationship between number of bacteria and their probiotic effects | |
Gao et al. | Changes in gut microbial populations, intestinal morphology, expression of tight junction proteins, and cytokine production between two pig breeds after challenge with Escherichia coli K88: a comparative study | |
Esposito et al. | Do children’s upper respiratory tract infections benefit from probiotics? | |
Rezazadeh et al. | The protective effect of Lactobacillus and Bifidobacterium as the gut microbiota members against chronic urticaria | |
Rad | Can probiotics prevent or improve common cold and influenza? | |
Chang et al. | Fructo-oligosaccharide alleviates soybean-induced anaphylaxis in piglets by modulating gut microbes | |
Vanderhoof | Probiotics in allergy management | |
CN111004733A (zh) | 一种具有缓解便秘功能的凝结芽孢杆菌复合微生态制剂 | |
Wang et al. | Effects of dietary supplementation of Lactobacillus delbrueckii on gut microbiome and intestinal morphology in weaned piglets | |
Yu et al. | Effects of Lactococcus lactis on the intestinal functions in weaning piglets | |
Zhang et al. | Fructooligosaccharides supplementation mitigated chronic stress-induced intestinal barrier impairment and neuroinflammation in mice | |
Rostami et al. | Efficacy of probiotics in prevention and treatment of infectious diseases | |
Bi et al. | Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial | |
Tanriover et al. | Use of probiotics in various diseases: Evidence and promises | |
Nagaraj et al. | Probiotics and oral health | |
Wang et al. | Effect of live Lactobacillus plantarum L2 on TNF-α-induced MCP-1 production in Caco-2 cells | |
CN110051702A (zh) | 一种防治手足口病、流感的益生菌配方 | |
Wang et al. | Therapeutic effect of Saccharomyces boulardii combined with Bifidobacterium and on cellular immune function in children with acute diarrhea | |
CN111544456A (zh) | 一种益生菌配方及其应用 | |
Pattanaik et al. | Probiotics, prebiotics, eubiotics and synbiotics for human and animal health and mitigation of antimicrobial resistance | |
Tong et al. | The Effect of BW2013 on The Gut Microbiota in Mice Analyzed by 16S rRNA Amplicon Sequencing | |
Bhunia | Bioengineered probiotics–A solution to broaden probiotics efficacy | |
Kim et al. | Gut Microbiota-Mediated Immunomodulatory Effects of Lactobacillus rhamnosus HDB1258 Cultured in the Lava Seawater in the Colitis Mouse Model | |
Meyer et al. | The role of pre-and probiotics in infant nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190726 |